MindWalk Holdings (HYFT) Other Non Operating Income (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Other Non Operating Income of -$284.51 for Q2 2026, up 4.96% year-over-year from -$271.06 in Q2 2025, and down 44.1% quarter-over-quarter from -$197.44 in Q1 2026.
MindWalk Holdings (HYFT) Other Non Operating Income (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Other Non Operating Income for 7 consecutive years, with -$284.51 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income rose 4.96% year-over-year to -$284.51; the TTM figure through Apr 2026 stood at -$798.55 (up 99.97% YoY), while the FY2026 annual figure was -$527.43, down 3.92% from the prior year.
- Other Non Operating Income fell to -$284.51 in Q2 2026 per HYFT's latest filing, from -$197.44 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $169.6 million in Q4 2023 and bottomed at -$2.9 million in Q3 2024.
- Historically, Other Non Operating Income has averaged $18.4 million across 5 years, with a median of -$240.97 in 2026.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 1263136.24% — and 2024, when it plunged 678.24%.
- MindWalk Holdings' Other Non Operating Income stood at $261254.7 in 2022, then soared by 64826.52% to $169.6 million in 2023, then sank by 100.1% to -$164032.7 in 2024, then soared by 99.82% to -$302.05 in 2025, then rose by 5.81% to -$284.51 in 2026.
- Business Quant data shows HYFT's Other Non Operating Income at -$284.51 in Q2 2026, -$197.44 in Q1 2026, and -$302.05 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -284.51 |
| Jan 31, 2026 | -197.44 |
| Oct 31, 2025 | -302.05 |
| Jul 31, 2025 | -14.56 |
| Apr 30, 2025 | -299.36 |
| Jan 31, 2025 | -74,669.25 |
| Oct 31, 2024 | -164,032.67 |
| Jul 31, 2024 | -2.92 Mn |
| Apr 30, 2024 | 65,639.30 |
| Jan 31, 2024 | -86,547.41 |
| Oct 31, 2023 | 169.62 Mn |
| Jul 31, 2023 | 163.33 Mn |
| Apr 30, 2023 | 132,289.80 |
| Jan 31, 2023 | -11,120.92 |
| Oct 31, 2022 | 261,254.71 |
| Jul 31, 2022 | 329,671.50 |
| Apr 30, 2022 | -720,863.84 |
| Jan 31, 2022 | 544,366.25 |
| Oct 31, 2021 | 20.68 |
| Jul 31, 2021 | 11,395.76 |